Who
Wellington Biomedical Innovation Master Investors (Cayman) II L.P.
10% owner
Company insider
Files Form 4 as: 10% owner, Avalyn Pharma; 10% owner, Metsera; 10% owner, Upstream Bio; 10% owner, MBX Biosciences; 10% owner, CARGO Therapeutics; 10% owner, RayzeBio.
In numbers
- Trades disclosed
- 18
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 6
- Companies where not an officer
- 6
- First trade
- 19 Sep 2023
- Last trade
- 1 May 2026
- Last filed
- 1 May 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 May 2026filed 1 May 2026 | AVLN Avalyn PharmaBiotechnology | SEC FORM 4 Code C | —1,275,486 | filing |
| 1 May 2026filed 1 May 2026 | AVLN Avalyn Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —20,482,289 at $0.00 | filing |
| 1 May 2026filed 1 May 2026 | AVLN Avalyn Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —4,060,259 at $0.00 | filing |
| 1 May 2026filed 1 May 2026 | AVLN Avalyn Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —20,482,289 at $0.00 | filing |
| 1 May 2026filed 1 May 2026 | AVLN Avalyn Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —4,060,259 at $0.00 | filing |
| 1 May 2026filed 1 May 2026 | AVLN Avalyn PharmaBiotechnology | SEC FORM 4 Code C | —1,275,486 | filing |
| 30 Jan 2025filed 3 Feb 2025 | Metseraoption or derivative | SEC FORM 4 Code C | —4,365,079 at $0.00 | filing |
| 30 Jan 2025filed 3 Feb 2025 | Metsera | SEC FORM 4 Code C | —1,857,699 | filing |
| 15 Oct 2024filed 15 Oct 2024 | UPB Upstream Biooption or derivative · Biotechnology | SEC FORM 4 Code C | —852,940 at $0.00 | filing |
| 15 Oct 2024filed 15 Oct 2024 | UPB Upstream BioBiotechnology | SEC FORM 4 Code C | —894,733 | filing |
| 16 Sep 2024filed 17 Sep 2024 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code C | —16,666,666 at $0.00 | filing |
| 16 Sep 2024filed 17 Sep 2024 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code C | —4,854,368 at $0.00 | filing |
| 16 Sep 2024filed 17 Sep 2024 | MBX MBX BiosciencesBiotechnology | SEC FORM 4 Code C | —1,386,335 | filing |
| 16 Sep 2024filed 17 Sep 2024 | MBX MBX BiosciencesBiotechnology | SEC FORM 4 Code C | —403,787 | filing |
| 14 Nov 2023filed 16 Nov 2023 | CARGO Therapeuticsoption or derivative | SEC FORM 4 Code C | —10,000,000 at $0.00 | filing |
| 14 Nov 2023filed 16 Nov 2023 | CARGO Therapeutics | SEC FORM 4 Code C | —737,000 | filing |
| 19 Sep 2023filed 19 Sep 2023 | RayzeBiooption or derivative | SEC FORM 4 Code C | —1,557,846 at $0.00 | filing |
| 19 Sep 2023filed 19 Sep 2023 | RayzeBio | SEC FORM 4 Code C | —1,557,846 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.